Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

Rhea-AI Summary

Enovis (NYSE: ENOV) has appointed Tim Czartoski as President of U.S. Surgical and Global Product and Enabling Technologies. Czartoski, who reports to Louie Vogt, Group President of Enovis' Reconstructive Business Group, brings over 22 years of experience from Depuy Synthes, Johnson & Johnson's Orthopaedics Company. In his previous role, he led Depuy Synthes' U.S. operations, overseeing joint reconstruction, trauma, spine, digital technology, capital, sports, and CMF businesses.

Czartoski's appointment is expected to accelerate Enovis' growth potential and strengthen its surgical pipeline globally. His educational background includes a B.S. from Ohio State University, an M.S. in Technology Management from Columbia, and an MBA from Notre Dame.

Positive

• Appointment of experienced MedTech executive with 22 years at Depuy Synthes
• Potential for accelerated growth and strengthened surgical pipeline
• New leadership brings strategic and commercial excellence to Enovis

Negative

• None.

News Market Reaction – ENOV

-1.01%

1 alert

-1.01% News Effect

On the day this news was published, ENOV declined 1.01%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company’s U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis’ Reconstructive (Recon) Business Group.

Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in leadership roles of increasing responsibility. In his most recent role as President of Depuy Synthes, U.S., Mr. Czartoski led the Company’s joint reconstruction, trauma, spine, digital technology, capital, sports and CMF businesses. He also served as the Worldwide President of Joint Reconstruction and Power Tools. 

Mr. Czartoski has a B.S. from Ohio State University, an M.S. from Columbia in Technology Management and an MBA from Notre Dame.

“Tim is a highly accomplished orthopedic leader with an incredible track record of delivering strategic and commercial excellence,” said Mr. Vogt. “I’m confident that his experience and leadership will accelerate Enovis’ growth potential and strengthen our surgical pipeline around the world.”

About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.

Media Contact
Katie Sweet, Vice President, Corporate Communications
Enovis
Katie.Sweet@enovis.com

FAQ

Who is Tim Czartoski and what is his new role at Enovis (ENOV)?

Tim Czartoski has been appointed as President of U.S. Surgical and Global Product and Enabling Technologies at Enovis (ENOV). He will be responsible for the company's U.S. Surgical business, including the global surgical product engine and enabling technologies.

What is Tim Czartoski's professional background before joining Enovis (ENOV)?

Tim Czartoski has over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson. His most recent role was President of Depuy Synthes, U.S., where he led the company's joint reconstruction, trauma, spine, digital technology, capital, sports and CMF businesses.

How might Tim Czartoski's appointment impact Enovis (ENOV)?

Enovis expects Tim Czartoski's appointment to accelerate the company's growth potential and strengthen its surgical pipeline globally. His experience and leadership in strategic and commercial excellence are anticipated to contribute positively to Enovis' performance.

What is Enovis (ENOV) and what does the company do?

Enovis (NYSE: ENOV) is an innovation-driven medical technology growth company. It focuses on developing clinically differentiated solutions for better patient outcomes and workflow transformation, with a particular emphasis on orthopedics and active lifestyles.